iBio, Inc. Common Stock earnings per share and revenue
On Nov 12, 2025, IBIO reported earnings of -0.11 USD per share (EPS) for Q1 26, missing the estimate of -0.10 USD, resulting in a -5.16% surprise. Revenue reached 100.00 thousand, compared to an expected 25.50 thousand, with a 292.16% difference. The market reacted with a -8.00% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of -0.10 USD, with revenue projected to reach 34.00 thousand USD, implying an decrease of -9.09% EPS, and decrease of -66.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
Twist Bioscience Corporation Common Stock
Report Date
Feb 02, 2026 For Q1 26
Estimate
-$0.43
Actual
-$0.50
Surprise
-14.00%
AYTU BioPharma, Inc. Common Stock
Report Date
Feb 03, 2026 For Q2 26
Estimate
-$0.61
Actual
-$1.05
Surprise
-71.57%
FAQ
What were iBio, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, iBio, Inc. Common Stock reported EPS of -$0.11, missing estimates by -5.16%, and revenue of $100.00K, 292.16% above expectations.
How did the market react to iBio, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -8%, changed from $1.25 before the earnings release to $1.15 the day after.
When is iBio, Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 09, 2026.
What are the forecasts for iBio, Inc. Common Stock's next earnings report?
Based on 6
analysts, iBio, Inc. Common Stock is expected to report EPS of -$0.10 and revenue of $34.00K for Q2 2026.